Life science is set to be one of the most important areas of 21st century innovation. The Nikkei Breakfast aims to show the revolutionary insights gathered for the meeting how scientists are leading the world in their research. By introducing the latest life science technologies, the meeting will illustrate the potential of the market and encourage international cooperation. So come to the breakfast to hear about the extraordinary, little-noticed developments especially in Japanese research which have the potential to shape the global scientific debate.
Nikkei Executive Breakfast
The next frontier in life science innovation
Dr. Shinya Yamanaka
Center for iPS Cell Research and Application (CiRA)
Dr. Nobuhiro Endo
Dr. Toru Kimura
Sumitomo Dainippon Pharma Co., Ltd.
In association with
Speakers and moderators include (5)
Dr. Shinya Yamanaka
Professor Shinya Yamanaka is most renowned for his discovery of induced pluripotent stem cells (iPSC), which are differentiated cells that have been reprogrammed back to the pluripotent state. He is Director of the Center for iPS Cell Research and Application (CiRA), which was founded in 2008 in response to his discovery, at Kyoto University, and named Senior Investigator at the Gladstone Institutes from 2007.
In recognition of his work, he has been the recipient of many prestigious awards including the Albert Lasker Basic Medical Research Award, the Canada Gairdner International Award, the 100th Imperial Prize and Japan Academy Prize, the Kyoto Prize, the Wolf Prize, the Japan Order of Cultural Merit, and the Breakthrough Prize. The significance of iPSC was culminated with Dr. Yamanaka being co-recipient of the Nobel Prize in Physiology or Medicine in 2012.
With the exception of a post-doctoral stay at the Gladstone Institutes from 1993 to 1996, he has lived and worked in Western Japan. Professor Yamanaka earned his M.D. from Kobe University in 1987 and began residency in orthopedic surgery. He then went to earn his Ph.D. from Osaka City University in 1993. It was at Gladstone where he first learned genetics and the use of embryonic stem cells. He returned to Osaka City University as staff until 1999 when he joined Nara Institute of Science and Technology (NAIST) and shifted his research focus to reprogramming. He was promoted to professor in 2003 and moved to Kyoto University in 2004.
He serves as a foreign associate of the NAS, fellow of the AACR, and member of EMBO, the Pontifical Academy of Sciences, and the Japan Academy.
Professor Yamanaka’s primary vision is to bring iPSC technology to human health care. Therefore, at CiRA, he has recruited a mixture of scientists conducting basic research and clinicians applying this research to disparate diseases and advocates the science regularly to the general public.
Dr. Nobuhiro Endo
Dr. Nobuhiro Endo was appointed Chairman of the Board of NEC Corporation effective April 1, 2016 after serving as President of the company from April 2010 to March 2016.
Before assuming the role of President, he served as Senior Vice President responsible for corporate strategy and business development, as well as held a key position in driving various management reforms within the NEC Group. Dr. Endo joined NEC in 1981 after receiving his Doctorate degree from the Graduate School of Science and Engineering at Tokyo Institute of Technology. Over the next two decades he engaged in the development of wireless communication systems for satellite communication systems and mobile phone base stations. In 2003, Dr. Endo played a leading role in the “PASOLINK” business, which eventually captured the No.1 global market share for ultra-compact microwave communications systems, by leveraging growth in emerging countries. Throughout his career, Dr. Endo has focused on driving innovation through advanced technologies for customers worldwide and building strong relationships with a diverse range of customers both in and outside Japan. Dr. Endo is known for his broad international perspectives gained through extensive experience in the global market and time spent living abroad.
Dr. Toru Kimura
Toru Kimura serves as a member of Sumitomo Dainippon Pharma’s board of directors, Senior Executive officer, Senior Executive Research Director of Drug Research Division, and Chief Research Officer. He is also responsible for Regenerative & Cellular Medicine Office, Kobe Center, and Manufacturing Plant. With more than 6,000 employees worldwide, Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan, with global operations in major markets including Japan, the U.S., China and the European Union.
Dr. Kimura joined Sumitomo Chemical Co., Ltd. in 1989 and the former Sumitomo Pharmaceuticals in 1992 as a scientist. Appointed to lead Sumitomo Dainippon Pharma’s Genomic Science Laboratories in 2009, he later served as a Director of the Global Strategy Group. Dr. Kimura established the company’s Regenerative & Cellular Medicine Office in 2013, overseeing stem cell research and development projects and external collaborations with academia and biotech partners.
Sumitomo Dainippon Pharma has conducted Regenerative Medicine/Cell Therapy research since the 1990s and currently has six R&D projects in these fields, primarily using iPS cells for neurological disorders, eye diseases and other serious medical conditions. In 2018 Dr. Kimura and his team completed the Sumitomo Dainippon Manufacturing Plant for Regenerative Medicine and Cell Therapy (SMaRT).
Dr. Kimura studied at Massachusetts General Hospital and Harvard Medical School as a visiting scientist, after earning a B.S. degree in Engineering Science from Osaka University and a Ph.D. in Science from Kyoto University.
Mr Christophe Weber
Christophe Weber is President and Chief Executive Officer of Takeda Pharmaceutical Company Limited. He joined Takeda in April 2014 as Chief Operating Officer, was named President and Representative Director in June 2014, and was subsequently appointed Chief Executive Officer in April 2015. Mr Weber has introduced key transformation changes within the global organisation which focus on the underlying principles of patient and customer-centricity, accountability and being as agile as possible for a global company. Mr Weber has held leadership roles across many different businesses and geographies. Prior to joining Takeda, Mr Weber held positions of increasing responsibility at GlaxoSmithKline (GSK) including President & General Manager at GSK Vaccines, CEO of GSK Biologicals SA in Belgium, and member of the GSK global Corporate Executive Team. From 2008 to 2010, Mr Weber served as Asia Pacific SVP and Regional Director at GSK Asia Pacific in Singapore. Mr Weber holds a doctorate degree in Pharmacy & Pharmacokinetics from the University of Lyon, France. There, he also earned Master’s degrees in Pharmaceutical Marketing and in Accounting and Finance, as well as a Bachelor’s degree in Statistics.
Gillian Tett is Chair, Editorial Board, and Editor-at-large, US at the Financial Times. She previously served as US Managing Editor, leading the Financial Times’ editorial operations in the region across all platforms. She writes weekly columns for the FT, covering a range of economic, financial, political and social issues throughout the globe. Ms Tett served as Assistant Editor, US Managing Editor from 2010 to 2012, and prior to this Assistant Editor responsible for the FT’s markets coverage. Other roles at the FT have included Capital Markets Editor, Deputy Editor of the Lex column, Tokyo Bureau Chief, Tokyo Correspondent, London-based economics reporter and a reporter in Russia and Brussels.
In 2014, she was named Columnist of the Year in the British Press Awards and also received the Royal Anthropological Institute Marsh Award. She is the author of The Silo Effect: Why Putting Everything In Its Place Isn't Such A Bright Idea (Simon & Schuster, 2015), New York Times bestseller Fool’s Gold: How Unrestrained Greed Corrupted a Dream, Shattered Global Markets and Unleashed a Catastrophe (Little Brown, UK and Simon and Schuster, US, 2009), and Saving the Sun: A Wall Street Gamble to Rescue Japan from Its Trillion Dollar Meltdown (Harper Collins, 2003). Before joining the FT in 1993, Ms Tett was awarded a PhD in Social Anthropology from Cambridge University, where she also earned her Bachelor’s degree.
Agenda - 21st Jan
Registration and networking breakfast
“New Era of Medicine with iPS Cells”
Shinya Yamanaka, Director, CiRA, Kyoto University
“The next frontier in life science innovation”
- Shinya Yamanaka, Director / Professor, CiRA, Kyoto University
- Nobuhiro Endo, Chairman of the Board, NEC Corporation
- Toru Kimura, Member, Board of Directors, Senior Executive Officer, Sumitomo Dainippon Pharma Co., Ltd.
- Christophe Weber, President and CEO, Takeda Pharmaceutical Company Limited
Moderator: Gillian Tett, Chair, Editorial Board and Editor-at-Large, US, Financial Times
Nikkei is a trusted media brand in Asia, known for its quality journalism and capability in providing business news and information. Founded as a market news media in Japan in 1876, Nikkei has grown to be one of the largest media conglomerates with 37 foreign editorial bureaus and approximately 1500 journalists worldwide, with another global media brand, the Financial Times, joining in our group in 2015. Nikkei is continually deploying new technology to find new ways to deliver news as a reliable source of information for the global community.
In Association with (1)
The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.
Host partner (3)
NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. Since its establishment in 1899, NEC has developed products and services that capitalize on the advanced technologies to create value for society.
Today, with approximately 110,000 employees and sales topping USD 26 billion, NEC is currently focusing on leveraging its strengths in information and communications technology (ICT) including its world-leading biometrics and AI to offer “Solutions for Society” capable of increasing the sophistication of infrastructure systems and services indispensable to society.
Under the company’s corporate message of “Orchestrating a brighter world,” NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow.
Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China and the European Union. Sumitomo Dainippon Pharma aims to create innovative pharmaceutical products in the Psychiatry & Neurology area, the Oncology area and Regenerative medicine/Cell therapy field, which have been designated as the focus therapeutic areas. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at https://www.ds-pharma.com.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality- diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com
Who should apply?
This exclusive Executive Breakfast is by invitation only.